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Loss of RB1 gene is considered either a causal or an accelerating event in retinoblastoma. A variety of mechanisms inactivates RB1 gene,
including intragenicmutations, loss of expression bymethylation and chromosomal deletions, with effectswhich are species–and cell type-
speciﬁc. RB1 deletion can even lead to aneuploidy thus greatly increasing cancer risk. The RB1gene is part of a larger gene family that
includes RBL1 and RBL2, each of the three encoding structurally related proteins indicated as pRb, p107, and p130, respectively. The great
interest in these genes and proteins springs from their ability to slow down neoplastic growth. pRb can associate with various proteins by
which it can regulate a great number of cellular activities. In particular, its association with the E2F transcription factor family allows the
control of themain pRb functions, while the loss of these interactions greatly enhances cancer development. As RB1 gene, also pRb can be
functionally inactivated through disparatemechanismswhich are often tissue speciﬁc and dependent on the scenario of the involved tumor
suppressors and oncogenes. The critical role of the context is complicated by the different functions played by the RB proteins and the E2F
family members. In this review, we want to emphasize the importance of the mechanisms of RB1/pRb inactivation in inducing cancer cell
development. The review is divided in three chapters describing in succession the mechanisms of RB1 inactivation in cancer cells, the
alterations of pRb pathway in tumorigenesis and the RB protein and E2F family in cancer.
J. Cell. Physiol. 228: 1676–1687, 2013.  2013 Wiley Periodicals, Inc.
The retinoblastoma (RB) gene RB1, located at chromosome
13q14.2, is part of a larger gene family that includes two other
RB-related genes designated as retinoblastoma-like 1 (RBL1)
and retinoblastoma-like 2 (RBL2). RBL1 is located at
chromosome 20q11.2, a region of special interest because of its
association with some myeloid disorders (Claudio et al., 2002);
RBL2 is located at chromosome 16q12.2, an area in which
deletions or loss of heterozygosity have been found in several
human neoplasms and correlated with clinical aggressiveness
(D’Andrilli et al., 2004). These three genes are structurally
related, each has the ability to suppress tumor cell growth in
vitro and several results suggest that, to manifest the fully
transformed phenotype of mammalian cells, their simultaneous
inactivationmay be required (Modi et al., 2000). RB1, RBL1, and
RBL2 genes encode structurally related proteins belonging to
the RB protein family, which are indicated as pRb, p107, and
p130. These proteins share extensive structural homology and
contain a conserved domain indicated as ‘‘pocket’’ (Chan et al.,
2001), which was originally identiﬁed as a region required to
bind viral oncoproteins, as adenovirus E1A (Ad-E1A), Simian
virus 40 large T antigen (SV40 LT-antigen) and human papilloma
virus E7 (HPV-E7; Moran, 1993). The pocket domain has been
thereafter described as required for the physical interaction of
RB proteins with a variety of cellular proteins believed to work
with RB proteins in transcriptional regulation, including human
D-type cyclins (Dowdy et al., 1993), BRG1 (Dunaief et al.,
1994), and HDAC1 (Brehm et al., 1998).
More than 750 reviews have been published on RB proteins
and more than 150 focused on RB proteins and cell cycle
control. Among them we want, in particular, to highlight the
comprehensive reviews of Cobrinik (2005) and Henley and
Dick (2012). These reviews extensively describe the key roles
played by the RB proteins in regulating the advancement of the
cell cycle fromG1 to S phase through negative regulation of E2F
transcription factors (E2Fs) and cyclin dependent kinases
(CDKs). The reviews report a great number of paper describing
the hypophosphorylated state of RB proteins (with binding and
inhibition of the E2F transactivation domain) and their
hyperphosphorylated state (with the release of E2F and the
expression of genes that mediate S phase entry). They also
describe how the E2Fs deregulation not only increases cell
proliferation, but also induces apoptosis, senescence,
checkpoint defects and altered DNA damage response, even
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preventing differentiation. The reviews also analyze the
regulation determined by pRb on cell cycle transitions through
E2F-independent mechanisms and its effect on the spatial
organization of genomic replication. The roles of RB proteins in
organisms as distantly related as humans, plants and insects are
reported.
As RB proteins are central to the regulation of cell
proliferation, deregulation of cell cycle control requires the
inactivation of their growth regulatory functions to favor cancer
onset.
Here, by our review, we wanted emphasize the importance
of the mechanisms of RB1/pRb inactivation for inducing cancer
cell development.
Brief history of the retinoblastoma disease and gene
The identiﬁcation of the retinoblastoma susceptibility gene
(RB1)—the ﬁrst tumor suppressor gene to be identiﬁed—was
a milestone in understanding cell cycle control and cancer
genetics (Wang et al., 1994; Sellers andKaelin, 1997).More than
50 years ago, a children’s tumor (the retinoblastoma) was
realized to sporadically occur in some patients, but to be
inherited in others (Falls and Neel, 1951). After that, one
important piece of the tumor suppressor gene story beganwith
the studies of Alfred Knudson at the MD Anderson Cancer
Center and Tumor Institute in Houston, on hereditary patterns
for childhood retinoblastoma. In this center, in 1971, Knudson,
after years of observing cases of childhood cancer and the
likelihood that certain heredity patterns played a role in them,
focused on retinoblastoma, a type of pediatric eye cancer. The
studies—developed examining the family histories of 48
patients with this rare cancer of the retinas—created the
foundation for the tumor suppressor hypothesis. Since then,
retinoblastoma has represented a prototype biological model
for the study of a class of oncogenes, in which tumor-
predisposing mutations are recessive to wild-type alleles
(Vogel, 1979). Now, Knudson is internationally recognized for
his ‘‘two-hit’’ model of cancer causation (Knudson, 1971),
which explained the relationship between the hereditary and
non-hereditary forms of a cancer and predicted the existence of
tumor-suppressor genes that can suppress cancer cell growth.
According to this model, two mutational events or two hits are
required for tumor onset: an individual may have inherited a
germline mutation from a parent and that would constitute the
ﬁrst ‘‘hit’’ leading to the cancer, then the disease would develop
only after a secondmutational event, or second ‘‘hit,’’ produced
either spontaneously or otherwise. Thus, to transmit
retinoblastoma predisposition to offspring, RB1 mutation must
be present in germ-line cells and one allele mutation must be
transmitted as an autosomal dominant trait (Bamne et al.,
2005). Tumor development will be initiated by inactivation of
the secondRB1 allele (Valverde et al., 2005;Macpherson, 2008);
indeed biallelic mutations in RB1 have been recognized as the
causative genetic alteration for retinoblastoma and,
accordingly, introduction of RB1 into RB1/ cells reduces
their ability to promote malignant transformation (Richter
et al., 2003). However, since mutations in the second allele can
occur independently in several cells, multiple tumor foci arise in
most individuals who have inherited a predisposing RB1
mutation and this predisposes patients to a variety of other
malignancies (Monteiro, 2003). In short, the manifestation and
transmissibility of retinoblastoma depend on the nature of the
ﬁrst mutation, its time in development, and the number and
types of cells that are affected.
It is very interesting to note that retinoblastoma, a relatively
rare cancer [approximately 4% of childhood cancer and less
than 1% of all human cancers (Abramson, 2005)], has
contributed, more than others, to the understanding of cancer,
dramatically changing theway cancer is studied and understood.
Studies on retinoblastoma also produced important scientiﬁc
advancement in the ﬁeld, as the identiﬁcation of the RB1 gene
locus in chromosome region 13q14.2 (Lalande et al., 1984), the
cloning of a DNA sequence with many of the properties
predicted for the retinoblastoma susceptibility locus (Friend
et al., 1986), and the identiﬁcation and subsequently cloning of a
4.7 kb RB1 transcript (Lee et al., 1987).
However, the large size of RB1 gene (about 200 kb) and its
multiple dispersed exons—27 exons with two of the introns
being extremely large (35 and 70 kb)—(Hong et al., 1989),
strongly complicatedmolecular screening strategies. Indeed, to
permit themolecular detection of chromosomal translocations
associated with retinoblastoma, it was necessary to construct a
long-range restriction map, with the use of infrequently cutting
restriction enzymes, ﬁeld inversion gel electrophoresis and two
cloned fragments from the ends of RB1 gene (Higgins et al.,
1989).
Although the two-hit hypothesis suggested that the ﬁrst few
years following birth reﬂects the time-interval for homozygous
RB1 mutation, a large number of cytogenetic and comparative
genomic hybridization studies have shown that RB1 inactivation
is not sufﬁcient for determining retinoblastoma. These studies
have suggested that mutations of both alleles of the RB1 gene
are necessary for retinoblastoma tumor initiation (Wang et al.,
1994) but not sufﬁcient for malignant transformation (Sellers
and Kaelin, 1997). Thus, additional mutational events (three
hits) are required for RB1/ cells to progress into a fully
malignant tumor (Corson and Gallie, 2007). In particular, in
mouse models of retinoblastoma, retinal tumors only develop
when RB1 is lost together with at least another RB-related
gene/protein (Robanus-Maandag et al., 1998); in humans, loss of
both copies of RB1 does not lead directly to retinoblastoma, but
to retinoma (Dimaras et al., 2008) with a low level genomic
instability and high expression of the senescence-associated
proteins as the inhibitor of cyclin-dependent kinase 4a
(p16INK4a) and the RB family member p130. This suggests that
other family members can enforce cell cycle exit and inhibit
tumorigenesis in the absence of RB1. However, as progressive
genomic instability leads to highly proliferative, clonal, and
aneuploid retinoblastomas, it is difﬁcult to clinically observe
stable retinoma (Dimaras et al., 2008).
Children with retinoblastoma have a high risk of developing
second cancers as soft tissue sarcoma, osteosarcomas,
melanoma, Hodgkin disease, leiomyosarcoma and prostate,
breast, brain, lung and buccal cavity (salivary gland and tongue)
cancers (Abramson, 2005). However, the tumor more
frequently associated to retinoblastoma is osteosarcoma with
individuals affected by hereditary retinoblastoma having an
approximately 1,000 times higher incidence of this tumor
(Berman et al., 2008), with loss of heterozygosity of RB1 locus
(60–70%) representing a poor prognostic factor (Feugeas et al.,
1996; Alonso et al., 2001).
Mechanisms of RB1 Inactivation in Cancer Cells
Cancer is a heterogeneous disease whose initiation and
progression is promoted by the aberration of genes that
regulate the most important cellular processes (proliferation,
adhesion, differentiation, death) devoted to maintain the
integrity of complex organisms, and RB1 loss is an important
step in cancer development (Friend et al., 1986).
There are a large variety of genetic, epigenetic and
chromosomal changes that accumulate in cancer cells, with the
cells of most malignancies even showing aneuploidy (D’Urso
et al., 2010). However, although it is well known that the
majority of human cancers progress through the gradual
accumulation of genetic and epigenetic alterations, the genetic
mechanisms that initiate carcinogenesis are not well
understood.
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Chromosomal abnormalities, RB1 deletion, and
cooperating mutational events
Constitutional chromosome alterations, deletion of tumor
suppressor genes and overexpression of oncogenes have been
increasingly regarded as key initiating events in human cancers
(Hansen and Cavenee, 1987; Chin et al., 2011). A study of
cancer incidence in a follow-up of 2561 patients with
constitutional autosomal chromosome deletions performed
during the period 1965–2002 (Swerdlow et al., 2008), describes
13q chromosomal-deletions in retinoblastoma cells, in sporadic
as well as constitutional cases (the latter having the deletion in
all cells of the body). This study strongly suggests that, when
constitutionally present, this deletion is the reason for greatly
increased risk of cancer. Moreover, genetic linkage studies of
chromosomal abnormalities in hereditary retinoblastoma
(focused on chromosome 13q14) supported the idea that
retinoblastoma is a recessive cancer where the abnormal
chromosome is inherited and the corresponding wild type
chromosomal segment is lost in tumor cells (Godbout et al.,
1983). Today, it is known that RB1 loss can lead to chromosome
segregation defects through a number of disregulations, among
which misregulation of the expression of genes important for
centrosome duplication, for mitotic checkpoint control or for
eterochromatin structure formation and maintenance (Sage
and Straight, 2010).
As centrosome maintains genomic integrity by enforcing
euploidy (Adon et al., 2010), centrosome ampliﬁcation
determines aberrant and multipolar mitotic spindles, by
increasing frequency of chromosome segregation errors,
aneuploidy, and chromosome instability. This contributes to
cancer biogenesis and progression by triggering reduced
expression of tumor suppressors and overexpression of
oncogenes. One of the mechanisms contributing to
centrosome ampliﬁcation is deregulated centrosome
duplication triggered by the G1-CDKs (Adon et al., 2010);
centrosome ampliﬁcation, is also associated with mutation or
loss of function of genes as TP53, STK15, RB1, and BRCA1
(Albertson et al., 2003). Moreover, several studies
demonstrated that the RB1 gene isolated from retinoblastoma
tumors contains intragenic mutations with premature stop
codons, in-frame deletions and point substitutions (DeCaprio,
2009).
Mutations in oncogenes and tumor suppressor genes could
play cooperative roles in initiation and progression of cancer
(Fig. 1). Large cancer-associated chromosomal deletions could
arise from selective pressure to attenuate the activity of
multiple genes (Xue et al., 2012). For example, since RB1 loss
leads to enhanced cell death, whereas TP53 loss facilitates cell
survival, the simultaneous disruption of RB1 and TP53 genes
seen in many tumors, suggest a cooperation between these
Fig. 1. Genetic perturbations in RB1, CDKN2, Tp53, and BRCA1 and BRCA2 locus cooperate in promoting tumor progression. Chromosomal
abnormalities affecting RB1 in combinationwithCDKN2, Tp53, and BRCA1 andBRCA2 delections cooperate in the establishment of a complex
scenario inwhich loss of function of key genes contributes to cancer initiation and progression. Using human retinoblastoma samples andmouse
models, it has been reported that RB1 gene deletion (described inA) initiates a process of retinoblastoma development throughout cooperating
mutationalevents involvingchromosome13, chromosome9,andchromosome17.This results in thedeletionof thegenes reportedonthedouble
DNA helix with consequent cancer progression.
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losses in determining cancer (Plisiecka-Hałasa et al., 2008).
Similar cooperations in determining cancer are suggested for
the disruption of p53 and pRb pathways observed in most
human cancer. In this regard, it is known that the CDKN2A/B
locus is involved in both the pRb and p53 pathways by encoding
both p16INK4a, a regulator of CDK4/6-mediated pRB
phosphorylation, and p14ARF, a modulator of Mdm2-mediated
degradation of p53 (Sharpless andDePinho, 1999).Moreover, it
has been demonstrated that CDKN2A deletion plays an
important role in the malignant behavior of a number of cancer
as gastrointestinal tumors (Haller et al., 2008), malignant
gliomas (Liu et al., 2011), mesothelioma (Jean et al., 2012) and
others. Using human retinoblastoma samples and mouse
models, it has been suggested that ARF is a key collaborator
with pRb in retinoblastoma suppression since RB1 gene
deletion initiates a process of cooperating mutational events
between pRb and ARF in promoting mouse retinoblastoma
(Conkrite et al., 2012). Comparing gene expression signatures
of normal retinas and retinoblastoma tumors from a number of
patients, microarray analysis associated with statistical and
bioinformatic analyses, suggested that the genes differentially
expressed in retinoblastoma mainly belong to DNA damage-
response pathways, including breast cancer associated genes
(BRCA1, BRCA2), ataxia telangiectasia mutated gene (ATM),
ataxia telangiectasia and Rad3 related gene (ATR), E2F and
checkpoint kinase 1 (CHK1) genes. In addition, novel pathways,
such as aryl hydrocarbon receptor (AHR) signaling, polo-like
kinases (Plks) and purine metabolism pathways are involved. Of
particular interest appears the involvement of AHR,CHK1, and
Plks, as several drugs that target these molecules are currently
available (Ganguly and Shields, 2010). In addition, using
genetically engineered mice, it has been shown (Szabova et al.,
2012), that inactivation of RB1 induces surface epithelial
proliferation with progression to stage I carcinoma, and that
additional biallelic inactivation and/or missense TP53 mutation
in the presence or absence of BRCA1/2 cause progression to
stage IV disease. Moreover, as in human serous epithelial
ovarian cancer, mice developed peritoneal carcinomatosis,
ascites, and distant metastases. This strongly suggested a
cooperation among RB1, TP53 and BRCA1 or BRCA2,
conﬁrming the scenario complexity of the molecular players
involved in cancer initiation and progression.
Overall, the results suggest that in the absence of normal RB1
gene, genomic instability and chromosomal aberrations
accumulate leading to tumor initiation, progression and
metastasis. Thus, the identiﬁcation of the combinations of
mutations that collaborate in the development and progression
of speciﬁc types of cancer can bring innovative contributions to
cancer research.
Alterations of pRb Pathway in Tumorigenesis
The human retinoblastoma protein pRb is a 928 amino acids
chain whose conserved pocket domain is a region that binds
various critical protein interactors, many containing an LXCXE
motif (Chan et al., 2001). This pocket domain has a small pocket
region, consisting of A and B domains separated by a spacer
region (Classon andDyson, 2001), which acts as transcriptional
repressor (Chow et al., 1996) and interacts with viral
oncoproteins (Hu et al., 1990). The small pocket domain
together with the C-terminal domain form the large pocket
region which is the growth suppressing domain of the RB family
proteins (Bremner et al., 1995). This pocket fragment permits
the interaction of pRb with E2F family transcription factors
allowing the suppression of their transcriptional activity and the
control of cell proliferation (Hiebert et al., 1992).
Intrinsic checkpoints represent one of the major design of
the cells to combat aberrant proliferation and to preserve
genomic stability, and checkpoints elimination results in cell
death, inﬁdelity of chromosome transmission, or increased
susceptibility to environmental perturbations, which can be the
cause of human cancers (Lavia et al., 2003). Key oncogenic
events in cancer can either directly perturb proteins that
regulate progression through cell cycle, or indirectly alter cell
cycle progression, through effects on pathways that impinge on
the cell cycle, with the G1-S checkpoint being a cardinal
process. As a consequence, cancer cells multiply when and
where they should not and this permits maintenance of DNA
damage and chromosomal imbalances with altered division
time.
Because of its pocket domain, pRb is a multifunctional
protein that can interact with a variety of proteins and this
implicates that it can regulate not only the cell cycle but also
other cellular activities among which DNA replication, cellular
senescence, differentiation, and apoptosis (Knudsen and
Knudsen, 2006). pRb participates in a regulatory network that
governs the cellular response to antimitogenic signals and acts
as the gatekeeper of the G1/S transition, with its deregulation
constituting one of the hallmarks of cancer. Alterations of the
pRb signaling pathway by activation of positive components as
G1 cyclins and CDKs, inactivation of negative components as
CDK inhibitors and p53, or by mutations in RB1 itself (Fig. 2),
have been detected in virtually all human cancers.
pRb phosphorylation/inactivation is mediated by CDK4/6
whose overexpression represents one way to induce cancer. A
number of results suggests the involvement of CDK4 gene in
tumorigenesis, and among these are (i), the suppression of
CDK4 can lead to terminal differentiation of erythroleukemia
cells, whereas its overexpression can induce uncontrolled cell
growth and malignant transformation (Xiong et al., 1993); (ii),
the ampliﬁcation and consequent overexpression of the CDK4
gene have been found in various cancers including different
types of sarcomas and glioblastomas (Khatib et al., 1993;
Collins, 1995); (iii), in humanmelanomas it has been identiﬁed a
somatic point mutation of CDK4 (Wo¨lfel et al., 1995) which
prevented the binding of theCDK4 inhibitor p16INK4a, but not
of p21 or of p27KIP1. This mutation can disrupt the cell-cycle
regulation exerted by the tumor suppressor p16INK4a; and
(iv), since CDK4 is inhibited by a series of inhibitory proteins
(among which p16INK4a), the lack of INK4a function, also
participates in this scenario (Perrone et al., 2005).
Thus, pRb can be functionally inactivated through disparate
mechanisms and the constitutive pRb hyperphosphorylation is
one of the major mechanisms (Chatterjee et al., 2004). This has
also been shown in human osteosarcoma MG-63 cells, where
aberrant gene expression keeps pRb protein constitutively
inactivated by hyperphosphorylation which strongly
contributes to uncontrolled cell proliferation (De Blasio et al.,
2005); this also occurs in human hepatocellular carcinoma
where pRb inactivation is associated with promoter
methylation of the p16INK4a gene (Maeta et al., 2005), or in
serous ovarian carcinomas where p53 and p16INK4a
overexpression and low expression of p21WAF1/CIP1 permit
to deﬁne the ovarian tumor grade (D’Andrilli et al., 2008).
The effects of RB1/pRb inactivation are species, tissues,
and cell type speciﬁc
Inactivation of either RB1 or pRb, also determine effects which
are species, tissues and cell type speciﬁc. For example, in
contrast to retinoblastoma patients, in mice inheritance of one
deleted copy of RB1 does not predispose to retinoblastoma,
but to increased risk of pituitary and thyroid cancers (Williams
et al., 1994a); deletion of both copies of RB1 results in ectopic
proliferation, apoptosis and impaired differentiation in
extraembryonic, neural, and erythroid lineages, culminating in
foetal death by embryonic day 14.5 (E14.5; Wu et al., 2003); in
trophoblast stem (TS) cells, but not in trophoblast derivatives of
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the placenta, pRb is required for normal development (Wenzel
et al., 2007). In these cells pRb would have a stem cell-speciﬁc
function and its critical role would be mediated by E2F3. The
speciﬁc loss of pRb in TS cells leads to an overexpansion of
trophoblasts, a disruption of placental architecture, and fetal
death by E15.5. pRb loss resulted in an increase of E2F3
expression, and the combined inactivation of pRb and E2F3 in
TS cells restored placental development and extended the life
of embryos to E17.5. Thus, the loss of pRb in TS cells would be
the deﬁning event causing lethality of pRb/ embryos and the
pRb pathway would play a critical role in the maintenance of a
mammalian stem cell population. In addition, germline
mutations in RB1 and TP53 is accompanied by
pinealoblastomas, pancreatic islet cell tumors, bronchial
epithelial hyperplasia and retinal dysplasia, suggesting that in
mice these mutations can cooperate in the transformation of
speciﬁc cell types (Williams et al., 1994b). Moreover, it seems
that neoplastic transformation of human cells require more
genetic changes than their murine counterpart; indeed,
perturbation of two signaling pathways (involving p53 and Raf)
sufﬁces for the tumorigenic conversion of normal murine
ﬁbroblasts, whereas perturbation of six pathways (p53, pRb,
PP2A, TERT, Raf, and Ral-GEFs) is needed for tumorigenic
conversion of human ﬁbroblasts (Rangarajan et al., 2004).
Differences were also evidenced in genetic alterations
involved in lung cancer development, depending on whether
the tumors were neuroendocrine or not. More precisely, 87%
of high-grade neuroendocrine lung carcinomas exhibit an
abnormal expression of pRb that is highly correlated with a loss
of heterozygosity at the RB1 locus. In contrast, in non-
neuroendocrine carcinomas, pRb is mainly inactivated through
loss of p16INK4a function and/or constitutive cyclin D1
activation. (Gouyer et al., 1998).
Moreover, there are tissues, as urothelial and retina in
humans (He et al., 2009) and pituitary and thyroid in mice
(Knudsen and Knudsen, 2006), that are signiﬁcantly more
susceptible than others to tumorigenesis arising with RB1
alterations. In these tissues, loss of pRb compromises critical
facets of proliferation such that tumors readily arise from a ﬁeld
of aberrant cellular proliferation. In some tissue types, loss of
pRb could abrogate differentiation programs, whereas in other
tissues pRb loss would compromise genomic stability in a
manner promoting tumorigenesis (Knudsen and Knudsen,
2006).
Overall, the development of malignancy, typically includes
disruption of pRb activity through one of the many mechanisms
that disrupt the p16INK4a–CDK4–cyclin D–pRb pathway. In
melanomas pRb is inactivated through loss of p16INK4a; in
retinoblastoma, prostate cancer and osteosarcoma, pRb is
inactivated through direct mutation or loss of the RB1 locus
(Nielsen et al., 1998); moreover, the alteration of key cell cycle
regulators more frequently associated to RB1 loss seems to
Fig. 2. MechanismofRB1/pRb inactivationand its effectsoncancer.Manydifferentmechanisms cancontribute toRB1/pRb inactivation: binding
of viraloncoproteins (SV40LT,E1A,andE7); lossofp16/INK4;p16INK4promoterhypermethylation; deletionofRB1 locus;pRbphosphorylation/
inactivationbyCDK4/CyclinD1.ExplorationofmolecularlinksbetweenRB1/pRbinactivationandcancerrevealedthatlossofpRbfunctioncausesa
disregulationofmolecularbrakes regulatingcell cycleprogressionandanupregulationofZEBprotein, transcriptional repressorof theE-cadherin
gene and key determinant of epithelial-mesenchimal transition.
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affect p16INK4a (Indovina et al., 2010), whose downregulation
was observed in 55% of retinoblastoma patients, and in 56% of
these cases at least oneof the parents bored the same alteration
in blood cells. Additionally, in most patients with p16INK4a
downregulation and in the parents with the same alteration,
analysis of p16INK4a promoter showed hypermethylation
(Indovina et al., 2010). Interestingly, 30% of human cancers that
harbor gain-of-function in Ras show loss of p16INK4a
expression, resulting in hyperphosphorylated/inactive pRb
which plays important roles in maintaining the proliferative
status of these cells (Williams et al., 2006). Thus, p16INK4a
alteration could be a novel inheritable susceptibility marker to
retinoblastoma and could open the way for the development of
new preventive and therapeutic strategies using demethylating
agents.
In human retinoblastoma Y79 cell line, the deregulated cell
proliferation originated by the absence of pRb appeared to be
strongly supported by both an authocrine loop IGFR/IGF1/
IRS1-dependent (Giuliano et al., 1996), and a constitutive
activation of Akt (D’Anneo et al., 2010). In the majority of lung
cancers pRb is inactivated through loss of p16INK4a–cyclin D–
CDK4/6–pRb pathway function. In particular, in the case of
non-small cell lung cancer (Na-Hye, 2008) pRb inactivation can
occur through distinct mechanisms including mutation,
excessive CDK activation, deregulated phosphorylation
through abnormal CDK4–cyclin D expression, and loss of
p16INK4a activity by aberrant promoter methylation or
homozygous deletions, or point mutations. In human
esophageal cancer and in small cell lung carcinoma (Yokota
et al., 1988) the inactivation of pRb is more frequently
dependent on altered RB1 mRNA. Deregulation of several
genes involved in cell cycle control has been reported in classic
Hodgkin lymphoma and an aberrant copy number of
chromosome 9with the loss of one ormore p16INK4a loci was
detected in several cases (Kim et al., 2006). Lack of pRb and
p16INK4a was observed in over 50% of squamous cell
carcinoma (SCC) of the tongue, the most common intraoral
malignancy, accompanied by overexpression of cyclin D1 and a
strong reciprocal relationship between pRb and p16INK4a
expression (Bova et al., 1999). In contrast, in SCC of the oral
cavity and pharynx related to HPV infection, where pRb is
inactivated by E7 and this results in an upregulation of p16
expression, this overexpression has been correlated to
favorable prognosis (Weinberger et al., 2006). Moreover, loss
of RB1 function by loss of heterozygosity has been reported in
glioblastomas, breast cancer, gastric carcinoma, renal
carcinoma, laryngeal cancer. About glioblastoma (the most
common and lethal primary malignant brain tumor), recently
(Dunn et al., 2012) extensive multiplatform genomic
characterization has provided a higher-resolution picture of the
molecular alterations underlying this disease. Among the 601
genes analyzed, the most signiﬁcant somatically mutated genes
were TP53, PTEN, NF1, EGFR, RB1, PIK3R1, and PIK3CA. This
analysis permitted the projection of identiﬁed alterations onto
known pathways revealing the high incidence of p53, pRb and
receptor tyrosine kinase (RTK)/Ras/phosphoinositide 3-kinase
(PI3K) pathway dysregulation, and conﬁrming previous work
that had delineated lesions in these critical cascades. The
studies show that glioblastoma represents several histologically
similar yet molecularly heterogeneous diseases, which
inﬂuences taxonomic classiﬁcation systems, prognosis and
therapeutic decisions.
Murine embryonic ﬁbroblasts are readily transformed by the
introduction of speciﬁc combinations of oncogenes; however,
the expression of those same oncogenes in human cells fails to
convert such cells to tumorigenicity. Using normal human and
murine embryonic ﬁbroblasts (Boehm et al., 2005) it has been
shown that the transformation of human cells requires several
additional alterations beyond those required to transform
comparable murine cells. The introduction of the c-Myc and H-
RAS oncogenes in the setting of loss of p53 function efﬁciently
transforms murine embryonic ﬁbroblasts but fails to transform
human cells constitutively expressing hTERT, the catalytic
subunit of telomerase. In contrast, transformation of multiple
strains of human ﬁbroblasts requires the constitutive
expression of c-Myc, H-RAS, and hTERT, together with loss of
function of the p53, RB1, and PTEN tumor suppressor genes.
These manipulations permit the development of transformed
human ﬁbroblasts with genetic alterations similar to those
found associated with human cancers and deﬁne speciﬁc
differences in the susceptibility of human andmurine ﬁbroblasts
to experimental transformation.
In tumor tissues of patients with non-small-cell lung
carcinoma (NSCLC), it has been observed (Akin et al., 2002) a
loss of expression of p16INK4a and/or pRb in 72 out of 95
patients, with 70 of them showing inverse correlation. Loss of
p16INK4a expression was found to be signiﬁcantly greater in
SCC than in adenocarcinoma cases, with pRb negative SCC
cases having signiﬁcantly shorter survival. These results
suggested that disruption of p16INK4a/pRb pathway is
frequently involved in NSCLC and that, in cases with SCC, pRb
expression loss may predict clinical outcome.
An additional level of control on the phosphorylation and
inactivation of the pRb seems to be dependent on the
peptidylprolyl isomerase Pin 1 (Rizzolio et al., 2013), which
regulates tumor cell proliferation allowing the interaction
between CDK/cyclin complexes and pRb through direct
interaction with the spacer domain of the pRb protein, and in
such a manner selectively boosting the switch from hypo- to
hyper-phosphorylated pRb. In addition, as shown in human
malignant glioma tissue and in Pin1 knockout mice,
synergistically with PI3K and CDKs, Pin 1 plays a critical role in
sustaining the complete phosphorylation of pRb.
It has been suggested that pRb inactivation can also
contribute to tumor progression by conversion to an invasive
phenotype. Indeed, it has been observed (Arima et al., 2008)
that loss or reduction of pRb expression in high-grade breast
adenocarcinomas, and knockdown of pRb by small interfering
RNA in MCF7 breast cancer cells, disrupts cell–cell adhesion
and induces a mesenchymal-like phenotype that is implicated in
the metastasis of primary tumors. This was strongly supported
by the ﬁndings that in human breast cancer cells depletion of
pRb induces downregulation of the adhesion molecule E-
cadherin and thereby triggers the epithelial–mesenchymal
transition. In addition, in RB1-inactive cells that exhibited a
mesenchymal-like morphology and were highly invasive, ZEB
proteins—transcriptional repressors of the E-cadherin gene—
were markedly upregulated. Moreover, depletion of ZEB in
RB1-inactive cells suppressed cell invasiveness and proliferation
and induced epithelial marker expression (Arima et al., 2012).
These results implicate ZEB in induction of the epithelial-
mesenchymal transition, and suggest that the inhibition of
epithelial mesenchymal transition would be a novel tumor
suppressor function of pRb.
The complexity of these regulatory mechanisms is
complicated by the different functions played by the RB family
members which in some circumstances function analogously,
while in other can play very distinctive roles (Genovese et al.,
2006; Neganova and Lako, 2008). Of the three pocket proteins,
p130 has the highest expression level in quiescent cells (G0;
Litovchick et al., 2007); under these growth conditions pRb
expression is low, but detectable in complex with E2Fs, while
p107 is nearly undetectable. In arrested cells, E2F4 is
sequestered by the p130 protein. As the cells pass the G1-to-S
transition, the levels of pRb and p107 increase and E2F4 now
associates with both of these regulators. Once the cells enter S
phase, free E2F is composed of an equal mixture of E2F4 and
E2F1 (Moberg et al., 1996). Overall, the evaluation of the
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expression levels of pocket proteins throughout the cell cycle
(Henley and Dick, 2012), suggest that while pRb works equally
well in both cycling and quiescent cells, instead, p130 works
exclusively in quiescent cells, and p107 works exclusively in
cycling cells.Moreover, similarly to pRb, even p107 and p130 act
in a cell-type-and tissue-speciﬁc manner. For example, in C33A
cervical cancer cells, the ‘‘mullerian inhibiting substance’’
inhibits cell proliferation by the induction of p107 and p130,
whereas similar effects are not played in OVCAR8 epithelial
ovarian cancer cell line (Barbie et al., 2003). The proliferation of
T98G human glioblastoma cells is inhibited by p130, but not by
pRb and p107 (Claudio et al., 1996). It can be stated that p130
has growth suppressive properties similar to yet distinctive
from those of pRb and p107 (Canhoto et al., 2000), and that
reduced levels of p130 are a powerful negative prognostic
factor in several malignancies, enclosed soft tissue sarcomas
and Burkitt lymphoma (De Falco et al., 2007; Masciullo et al.,
2008).
Activation of the Ras oncogenic pathway and/or inactivation
of pRb pathway are involved in most human cancers.
Interestingly (Williams et al., 2006), Ras-induced oncogenic
transformation seems to depend on functional pRb as tumors
that have Ras mutations, usually keep expression of a wild-type
pRb. Indeed, ﬁbroblasts lacking pRb are less susceptible to the
oncogenic actions of Ras than wild-type cells, and activated Ras
has an inhibitory effect on the proliferation of pRb-deﬁcient
human tumor cells. In contrast, ﬁbroblasts deﬁcient in p107 and
p130 are more susceptible to Ras-mediated transformation
than wild-type cells. Moreover, loss of pRb in tumor cells
harboring a Ras mutation results in increased expression of
p107, which strongly inhibits proliferation of these tumor cells.
These ﬁndings that pRb and p107 have distinct roles in Ras-
mediated transformation suggested a novel tumor-suppressive
role for p107 in the context of activated Ras.
In distinct epithelia as mammary gland, brain choroid plexus
and prostate, pRb/p107/p130 inactivation induces aberrant
proliferation and apoptosis (Hill et al., 2005). However, in
mammary gland and brain choroid plexus, apoptosis is p53
dependent and tumors progress with selective inactivation of
p53 (Simin et al., 2004). Instead, the apoptosis induced in the
suppression of prostate tumor growth is regulated by the
tumor suppressor PTEN (Hill et al., 2005), which was found
mutated in a large number of cancers. In particular, it seems that
inactivation of pRb initiates prostate cancer with the
establishment of selective pressures that lead to diminished
PTEN function and tumor evolution. Thus, although the
biological effect of pRb inactivation is similar in all three
epithelial cell types, the pathways onwhich selective pressure is
imposed is distinct.
RB1 deletion also shows a great impact on mitogen
dependence, anchorage dependence and overall survival which
are inﬂuenced by the oncogene milieu.
Recently, employing a model of conditional genetic deletion
(RB1 loss and Ras-transformed cells) to decipher the effects
related to disease progression, it has been suggested that the
impact of RB1 deletion is dependent on the oncogene milieu,
and can directly contribute to transformed phenotypes and
response to therapeutic intervention (Dean et al., 2010). More
precisely, RB1 deﬁciency predisposed c-Myc-expressing cells to
cell death and reduced tumorigenic proliferation. In contrast,
RB1 deﬁciency exacerbated the tumorigenic behavior of Ras-
transformed cells either in themodel systemor in human tumor
cell lines. In addition, the evaluation of the sensitivity to cell
death with RB1 loss showed that, although under
pharmacological activation of the p53 pathway these Ras-
transformed-RB-deﬁcient cells bypassed the G1-checkpoint,
they were also highly sensitized to cell death.
Chellappan et al. (1992) have shown that inactivation of pRb
may be also determined by the transforming proteins of DNA
tumor viruses such as the SV40 LT-antigen and HPV-E7 which
target pRb during cellular transformation. In particular, they
showed that HPV-E7 protein and the SV40 LT-antigen can
dissociate the E2F-pRb complex. Moreover, since they found
that the E2F-pRb complex is absent in various human cervical
carcinoma cell lines that either express the E7 protein or harbor
an RB1 mutation, they suggested that the loss of the E2F-pRb
interaction through thismechanismmay be an important aspect
in human cervical carcinogenesis, also suggesting that this
dissociating action may initiate the oncogenic process in a
manner analogous to the mutation of the RB1 gene.
Importantly, functional inactivation of pRb by viral oncoprotein
binding is usually occurring in many neoplasias such as cervical
cancer, mesothelioma and AIDS-related Burkitt’s lymphoma
(Masciullo et al., 2008).
Overall, the results suggest that antigrowth signals directed
to pRb and cell cycle, are blocked in the majority of human
tumors, thus preventing cells from exiting the cell cycle and
entering G0. In short, different tumors exhibit selective
alterations of the pRb pathway, as overexpression of CDK4–6,
inactivation of p16INK4a, increased expression of cyclin D1,
mutation of CDK4 or direct mutational inactivation of RB1.
Whydifferent tumors preferentially select for alterations in one
component over the other is still unknown.
pRb and E2F Family in Cancer
Increasing evidence suggests that transcription factors (TFs)
can be usefully employed as markers for cancer, potential
prognostic markers, and targets for drug therapy. Deregulation
of TFs that control the G1-S transition by engaging E2F activity,
has been frequently evidenced in the process of neoplastic
transformation where E2Fs can act both dependently and
independently of cell cycle regulation (Chen et al., 2009) and can
also play crucial roles in timely activation of G1/S and G2/M
genes involved in cell cycle progression (Bracken et al., 2004;
Westendorp et al., 2012).
RB pocket proteins and E2F transcription factors
The mammalian E2F family has eight members (Chen et al.,
2009; Lammens et al., 2009, with references herein) which,
based on structure–function studies in vitro, have been
subdivided both into activators (E2F1–3a) and repressors
(E2F3b–8) members and into typical (E2F1–6) and
atypical(E2F7–8) members (Fig. 3). E2F1–6 members regulate
transcription of their target genes by bounding to their
promoters as dimers with a dimerization partner (DP) protein.
This is possible because they possess one N-terminal DNA-
binding domain (DBD) which is followed by a dimerization
domain allowing interaction with DP1, DP2, or DP3.
Heterodimerization, which is mediated by the leucine zipper
(LZ) and the marked box (MB) domains, is a prerequisite for
sequence-speciﬁc binding of these E2F proteins to the target
genes. Moreover, E2F1–5 function through pocket protein
binding domain present in the carboxyl-terminals, whereas
since E2F6 do not possess this domain, it acts as a negative
regulator countering the activity of other E2F members
(Gaubatz et al., 1998).
E2F7–8 bind to promoters as homodimers or heterodimers
without DP. This is possible because they have a duplication of
the DBD (DBP1 and DBP2) each containing DNA-binding and
dimerization sites (Logan et al., 2004).
Pocket proteins/E2F complexes are dynamic and change
upon progression through the cell cycle. Apparently, the only
clear biochemical distinctions between pRb and the related
p107 and p130 pocket proteins are their E2F-binding
preferences. In particular, in vivo, under normal conditions,
E2F1–3 bind exclusively to pRb (Lees et al., 1993),whereas E2F4
can associate with all pocket proteins (Moberg et al., 1996) and
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E2F5 (although can also interact with p107) preferentially
associate to p130 (Hijmans et al., 1995). However, in the
absence of E2F4, the E2F1 and E2F3 activators, which normally
do not bind p107 and p130, could now be recruited into a
complex with these pocket proteins. The consequence of this
pocket protein–E2F rearrangement is the sequestration of E2F
activators into a protein complex that has a repressor function,
raising the possibility that activators could compensate for
repressors and vice versa in a context-dependent manner
(Chen et al., 2009).
Roles of the E2F1–E2F3 members
In mice, the tumor suppressive properties of pRb are primarily
dependent upon its ability to inhibit the activity of E2F1–3.
Indeed, as shown by Chong et al., (2009), E2F1–3 play distinct
roles in dividing versus differentiating cells and in normal versus
cancer cell. In dividing progenitor cells, free E2F1–3 function as
transcriptional activators, but, contrary to the current view,
they are necessary for cell survival while are dispensable for cell
division. Instead, in differentiating cells E2F1–3 act as repressors
in a complex with pRb to silence E2F targets and facilitate cell
cycle exit. In differentiating cells the inactivation of pRb results
in a switch of E2F1–3 from repressors to activators, leading to
ectopic cell divisions. Overall, the results suggest that, when
associated with RB family members, E2F1–3 function as
transcriptional repressors, whereas free E2F1–3 activates
transcription. However, as mice lacking E2F1, E2F2, or E2F3
survive to mid gestation without global defects in the cell cycle,
this suggests that under normal conditions E2Fs do not
substantially contribute to the proliferative potential of a cell
(Chen et al., 2009).
Deregulated E2F1 activity, as a consequence of pRb or
p16INK4a inactivation or ampliﬁcation of cyclin-D or CDK4,
confers growth advantage to cancer cells and is a hallmark of
human tumors (Wu and Yu, 2009). The study of Worku et al.
(2008) demonstrated a compelling trend for lower level of
expression of E2F1 gene in malignant versus normal tissues.
Remarkably, it has been established a statistically signiﬁcant
inverse correlation between the expression of E2F1 genes and
increasing TNM (Tumor, Node, Metastasis) stage of breast
cancer. Such downregulation of E2F1 in malignant tissues
suggests a tumor suppressive role for E2F1 in human normal
tissues. In addition to cell proliferation control, E2F1 can also
induce apoptosis under various cellular contexts. However,
although it is well known that E2F1 is a proapoptotic factor, the
mechanisms regulating its proapoptotic activity are not fully
understood. In human retinoblastoma Y79 cells (Drago-
Ferrante et al., 2008), the potent apoptotic effect induced by the
anticancer drug paclitaxel (PTX) was accompanied by a potent
Fig. 3. CrosstalkbetweenE2F familyproteinsandpRb.Full-lengthpRb(aminoacids1–928) isdepictedat thetopwith the largeA/Bpocketwhich
wasoriginallydeﬁnedonthebasisof itsabilitytointeractwithE2FtranscriptionfactorsonDNA.E2Fsareafamilyofproteinsthatshareaconserved
DNA-bindingdomain (DBD) thatbinds tooverlapping setsof targetpromoters.EightE2F familymembers (E2F1–8)havebeendescribed.E2F1–6
contain a conserved dimerization domains and form DNA-binding heterodimers with proteins of the differentiation-regulated transcription
factor-1polypeptide(DP) family.MembersofE2F1–5containC-terminaldomains thatmediate interactionswiththepocketdomainsofRB-family
proteins.E2F6–8donotpossessthisdomain.E2F1–3bshareanuclear localizationsignal (NLS)at theiramino-terminaldomains. Instead,E2F4and
E2F5 have a nuclear export signal (NES). E2F7 and E2F8 possess two DBD and do not have pocket protein binding domains. E2F1–3a seem to
primarily function as transcriptional activators; E2F3b–8 seem to primarily function as transcriptional repressors.
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induction of E2F1 andwas followedbyG2/M arrest, and cyclines
A, E, and B1 accumulation. This was also accompanied by a
prolonged increase in p53 expression and stabilization, with its
nuclear translocation and increases in the levels of its
transcriptional targets (p21WAF1, bax, and MDM2). In human
H1299 non-small lung carcinoma cells (Xie et al., 2006) E2F1
promoted p53-independent apoptosis through directly
regulating Smac/DIABLO, its downstream mitochondrial
apoptosis-inducing factors. Recently (Aoki et al., 2012), it has
been shown that E2F family are covalently conjugated with
NEDD8 a member of the ubiquitin-like protein family.
Following DNA damage SENP8 (a cysteine protease that
speciﬁcally cleavesNEDD8 frommodiﬁed substrates) removed
NEDD8 from E2F1. This stronglymodiﬁed the target speciﬁcity
of E2F1, enhancing its activity at a subset of target genes
including p73. Thus, deNEDDylation has been suggested as a
critical switch that directs E2F1 toward proapoptotic function.
Moreover, Shi et al. (2011) have shown that resveratrol (a
natural polyphenolic compound with cancer chemopreventive
activity) induced apoptosis in breast cancer cells by E2F1-
mediated upregulation of ASPP1, a new member of the ASPP
(apoptosis stimulation protein of p53) family, which plays an
important role in the regulation of apoptosis. Shortly, as p53 is
frequently inactivated in human cancers, E2F1-induced
apoptosis has been suggested as an additional tumor
surveillance mechanism to protect the organism from tumor
development.
Also concerning the E2F2 role, studies in mice and humans
have suggested that it can function as a tumor suppressor. It has
been shown that E2F2 transcriptionally represses cell cycle
genes to establish the G0 state (Infante et al., 2008). Indeed
disruption of the E2F2 gene causes T cells and murine
embryonic ﬁbroblasts to enter S phase early and to undergo
accelerated cell division. E2F2 also functions as a tumor
suppressor in epithelial tissues by limiting proliferation in
response to Myc (Pusapati et al., 2010). In fact, in the skin and
oral cavity, E2F2 inactivation cooperates with transgenic
expression of Myc to enhance tumor development without
affecting Myc-induced apoptosis. Pusapati et al. (2010) also
show that E2F2 differentially regulates gene expression
depending on the individual target in epidermal keratinocytes,
thus conﬁrming the critical importance of cell type speciﬁcity in
cancer mechanisms.
E2F3 has emerged as a critical pRb-binding factor, important
for mediating many of pRb functions during embryonic
development and tumorigenesis. The E2F3 locus drives the
expression of two related gene products, E2F3a and E2F3b,
through the use of two distinct promoters. E2F3a protein
accumulates maximally at the G1/S transition, whereas E2F3b
protein is expressed in quiescent cells and remains constant
throughout the cell cycle, this can explain the importance of
E2F3 in mediating pRb function (Adams et al., 2000). E2F3 is a
candidate bladder cancer oncogene, with overexpression of its
isoforms (E2F3a and b) being evidenced in 6p22-ampliﬁed
bladder cell lines (Hurst et al., 2008). However, in primary
bladder tumors, the presence of hyperphosphorylated pRb
formor the loss in p16INK4a suggested that, in addition to E2F3
overexpression, inactivation of the pRb pathway is required for
these tumors. Recently it has been demonstrated that the
strength of E2F3 expression is a potential marker for
discriminating prostate benign and malignant disease (Pipinikas
et al., 2007).
Roles of the E2F4–E2F6 members
E2F4 and E2F5 species are very poor transcriptional activators
and they are unable to induce quiescent cells to enter S phase.
They can form complexes with pRb, p107, and p130 and in this
form can bind to E2F-responsive promoters and actively
repress their transcription, thereby promoting quiescence
(Dyson, 1998). E2F4, the most abundant E2F protein, has a
transactivation domain but, due to the presence of strong
nuclear export signals, in its free form is primarily localized to
the cytoplasm and thus its transcriptional activity is restrained.
In the G0/G1 phase of cell cycle E2F4, owing its interaction with
the pocket proteins, accumulates in the nucleus where actively
represses E2F-target (Gaubatz et al., 2001). E2F4 and pRb
functionally interact in speciﬁc neuroendocrine tissues to
restrain cell proliferation and it has been established a role for
these proteins in the urogenital epithelium and in derivatives of
neural crest cells (Parisi et al., 2009). In RB/ E2F4/
chimericmice, loss of E2F4 differently affects the tumorigenicity
of pRb-deﬁcient tissues. Themost striking effectwere observed
in the pituitary where E2F4 loss delays the development, and
reduces the incidence of pRbmutant tumors (Parisi et al., 2009).
Regarding E2F5, Kothandaraman et al. (2010) investigated
the involvement of E2F5 in the development of ovarian
epithelial cancer (OEC), the most lethal gynecological
malignancy in Western countries. Performing the study on a
great number of women differently aged (20–72 years) with
either normal, benign, or malignant tumors, they
unambiguously showed that malignant tissues overexpress
E2F5, while none of the normal and benign samples showed
expression for E2F5. More precisely, E2F5 was found to be
upregulated (ﬁvefold) in early and late stage of ovarian tumors.
As E2F5 falls in the E2Fs category of inhibitors of proliferation,
the authors suggested that the increased E2F5 levels might be
the result of an attempt of the body to arrest the proliferation of
tumor cells during the early stage of the disease. The study
suggests that high E2F5 levels in tissues and serum can be a
potential marker for early OEC.
Recently, it has been shown that E2F5 positively regulates S-
phase entry in HeLa cells and that this activation of the cell cycle
is speciﬁc for HPV18-expressing cells. This suggested that
HPV18 could act changing the role of E2F5 from being a cell-
cycle repressor to an activator, thus contributing to the higher
oncogenic potential of HPV18 respect to other high-risk HPV
types (Teissier et al., 2010).
E2F6, similarly to the other E2F1–5 members, binds to E2F
consensus sites, but in contrast to these members, it lacks an
pRb binding domain and functions as an pRb-independent
transcriptional repressors (Pohlers et al., 2005). Consistent
with this ﬁnding, E2F6 can behave as a dominant negative
inhibitor of the other E2F family members. The biological
properties of E2F6 are mediated through its ability to recruit
the polycomb transcriptional repressor complex which plays a
well-established role in gene silencing (Attwooll et al., 2005).
Oberley et al. (2003), using a combination of chromatin
immunoprecipitation and genomic microarrays, have shown
that many of the E2F6-regulated genes encode functions
involved in tumor suppression and maintenance of chromatin
structure.
In short, it is thought that genetic alterations resulting in the
loss of pRb functions cause cancer by unleashing E2F activity and
deregulating cell proliferation. However, given that a number of
human tumors have concurrent pRb inactivation and E2F
ampliﬁcation and overexpression, it is possible that the E2F
family can have alternative tumor-promoting activities
independent of cell cycle regulation.
The atypical E2Fs family members E2F7 and E2F8
Recently, a novel evolutionarily conserved branch of E2F-
related TFs has been discovered which, owing to their peculiar
structural properties, were designated atypical E2F proteins. As
described by Lammens et al. (2009), these atypical E2Fs family
members (E2F7 and E2F8), have a duplicated DBD and control
gene expression without heterodimerization with partner
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proteins. They are involved in post-mitotic development,
embryogenesis and carcinogenesis also playing crucial functions
during development (control of cell size, endocycle,
proliferation and DNA-damage response). Given their crucial
role in controlling proliferation, proper mitotic entry and
DNA-damage induced apoptosis theymight function as putative
tumor suppressors in the tumor setting. In addition (Moon and
Dyson, 2008) it seems that these proteins, together with E2F1,
form a cell-cycle-dependent feedback loop in which the
transcription of E2F7 and E2F8 increases at the G1/S phase
transition along with other E2F targets. Then, as E2F7 and E2F8
accumulate, in turn repress the transcription of E2F1, limiting
the level and window of E2F1 activity. Additionally, Li et al.
(2008) have shown that for mice cell survival and embryonic
development, it is essential that E2F7 and E2F8 synergize.
In ovarian tumor tissues low levels of E2F7 have been
associated with low patient survival and potential development
of resistance to anticancer drugs (Reimer et al., 2007). Recently,
Westendorp et al. (2012) employing the combination of two
independent genome-wide approaches (ChIP-seq technology
and short term induction of E2F7), identiﬁed 89 target genes
that carry E2F7 binding sites close to the transcriptional start
site and thatwere directly repressed by short-term induction of
E2F7. These genes, which were considered as the top E2F7
target genes, encode gene products involved predominantly in
DNA replication, metabolism and DNA damage response
(RAD51, CHEK1, and BRCA1–2 genes). Since the transcription
of themajority of the E2F1–3a target genes is repressed directly
by E2F7, the authors suggested that E2F7 counterbalances the
transcription of E2F target genes activated by E2F1–3a. They
also showed that protein levels of E2F7 accumulatemaximally at
mid to late S-phase coinciding with the time when the
expression of E2F target genes declines. Conclusively, they
stated that classical E2F activators are essential for the upswing
in the oscillating pattern of the cell cycle-speciﬁc expression of
G1/S genes, whereas the atypical E2Fs contribute directly to the
downswing. In sharp contrast to E2F7, high levels of E2F8 are
correlatedwith poor survival in glioma patients (Lammens et al.,
2009). Moreover, Deng et al. (2010) have reported that E2F8 is
strongly upregulated in human hepatocellular carcinoma
(HCC), where it contributes to oncogenesis and progression
and have suggested that E2F8 contributes to the oncogenic
potential of HCC, thus constituting a potential therapeutic
target in this disease.
Conclusions
Themechanisms of RB/pRb inactivation and the loss of pRb/E2F
interaction found in cancer evidence that the intervention of
these molecules in cell cycle control is a basic event to avoid
cancer and that these inactivating mechanisms cause cancer by
unleashing E2F activity. However, given that a number of human
tumors have concurrent pRb inactivation and E2F
overexpression, it is possible that the E2F family can have
alternative tumor-promoting activities independent of cell cycle
regulation, so how it is possible that pRb can play its regulatory
roles independently of E2F family. Importantly, the effects of
RB1/pRb inactivation are species, tissues and cell type speciﬁc,
and the complexity of these regulatory mechanisms is
complicated by the different functions played by the RB and E2F
family members. Anyway, the deregulation of the roles played
by RB proteins and E2Fs leads to cancer development. It seems
that the majority of human tumors can block all the antigrowth
signals directed to pRb and cell cycle, thus preventing cells from
exiting the cell cycle and entering G0. Moreover, although the
reason is still unknown, it is well known that different tumors
preferentially select for alterations in one component over the
other. Thus, despite the nearly 6,000 papers published on RB in
cancer, more studies are needed to understand how pRb can
contribute to cancer origin and development. This may lead to
design novel therapeutic strategies.
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